ロード中...
PHASE II STUDY OF CELECOXIB AND DOCETAXEL IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH PROGRESSION AFTER PLATINUM-BASED THERAPY
INTRODUCTION: To evaluate the efficacy and toxicity of the combination of celecoxib and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) after failure of platinum-based therapy. METHODS: Patients with relapsed NSCLC received celecoxib 400 mg orally twice daily beginning 7 days...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2008
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3771331/ https://ncbi.nlm.nih.gov/pubmed/19057272 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31818de1d2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|